Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models - KIVIRID

Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models

Authors: Yunhua Zhou, Jun Yao, Rong Shi, Yang Qiu, Haiqing Hua

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-2888

Source: Full article

Abstract

Background: